<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02219893</url>
  </required_header>
  <id_info>
    <org_study_id>ImmunoPeCa Trial</org_study_id>
    <nct_id>NCT02219893</nct_id>
  </id_info>
  <brief_title>Immunotoxin in Peritoneal Carcinomatosis- ImmunoPeCa Trial</brief_title>
  <acronym>ImmunoPeCa</acronym>
  <official_title>Phase I/II Trial of MOC31PE Immunotoxin in Peritoneal Carcinomatosis From Colorectal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is through a phase I/II clinical trial to assess the safety and&#xD;
      toxicity of intraperitoneally administered MOC31PE immunotoxin, given on the 1.postoperative&#xD;
      day after cytoreductive surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)&#xD;
      for peritoneal metastases from colorectal cancer (CRC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MOC31PE is an immunotoxin that has previously been evaluated in a phase I clinical study&#xD;
      involving patients with advanced EpCAM positive carcinoma to assess the safety and&#xD;
      tolerability profile and the pharmacokinetic behavior of the compound. In this study, the&#xD;
      compound was administered intravenously and was well tolerated. MOC31PE will now be evaluated&#xD;
      on the same parameters in a new phase I/II clinical trial, where the drug will be&#xD;
      administered intraperitoneally to patients with peritoneal metastases from EpCAM positive&#xD;
      colorectal carcinomas.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">December 10, 2016</completion_date>
  <primary_completion_date type="Actual">December 10, 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>5 years or until disease progression</time_frame>
    <description>Follow-up: 5 years from administration of study drug, or until disease progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax, Tmax</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measurements will be done at 0, 3, 6, 12, 24, 48 and 72 hours after administration of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing anti-immunotoxin antibody response</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measurements of neutralizing anti-immunotoxin antibody response will be done at 4 and 8 weeks after administration of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of disease recurrence</measure>
    <time_frame>5 years or until disease progression</time_frame>
    <description>Serum samples for identification of biomarkers of disease recurrence will be taken at every follow-up for 5 years or until disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival of all patients will be assessed after 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Follow up period of 5 years, or until disease progression</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <arm_group>
    <arm_group_label>MOC31PE Immunotoxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug to be instilled on day 1 after cytoreductive surgery and HIPEC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MOC31PE Immunotoxin</intervention_name>
    <description>Patients who meet inclusion criteria will be treated with a single intraperitoneal MOC31PE immunotoxin instillation for 6 hours on the first day after CRS and HIPEC</description>
    <arm_group_label>MOC31PE Immunotoxin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Histologically verified EpCAM positive colorectal cancer&#xD;
&#xD;
          -  Ambulatory with Eastern Cooperative Oncology Group (ECOG) performance status 0-1 at&#xD;
             the time of surgery&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Suspected isolated peritoneal carcinomatosis upon radiologic work-up&#xD;
&#xD;
          -  Complete cytoreduction at surgery and mitomycin C given as standard HIPEC procedure&#xD;
&#xD;
          -  Peritoneal Cancer Index (PCI) ≤ 20&#xD;
&#xD;
          -  Laboratory values at inclusion:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) &gt; 1.5 x 10^9/L&#xD;
&#xD;
               -  Platelets &gt; 100 x 10^9/L&#xD;
&#xD;
               -  Hb &gt; 9g/dL&#xD;
&#xD;
               -  Creatinine ≤ 2x upper limit of normal&#xD;
&#xD;
               -  Bilirubin &lt; 2.0x the upper limit of normal&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 2. 5x the&#xD;
                  upper limit of normal&#xD;
&#xD;
               -  Albumin levels &gt; 30 g/L&#xD;
&#xD;
               -  International normalised ratio (INR) &lt;1.3&#xD;
&#xD;
          -  Signed informed consent and expected cooperation with respect to treatment and&#xD;
             follow-up must be obtained and documented according to International Conference of&#xD;
             Harmonisation- Good clinical Practice (ICH GCP), and national/local regulations.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Other synchronous metastatic lesions. Patients may be included if they have had&#xD;
             curative resection of metastatic CRC disease more than 2 years prior to inclusion and&#xD;
             have no relapse at this location is detected.&#xD;
&#xD;
          -  History of prior other malignant disease the last 3 years, except for adequately&#xD;
             treated carcinoma of the cervix or basal or squamous cell skin cancer.&#xD;
&#xD;
          -  History of central nervous system (CNS)- or bone metastases&#xD;
&#xD;
          -  Significant cardiac or other medical illness that would limit activity or survival,&#xD;
             such as severe congestive heart failure, unstable angina, or serious cardiac&#xD;
             arrhythmia&#xD;
&#xD;
          -  History of any liver disease including Hepatitis B or C infection&#xD;
&#xD;
          -  Chemotherapy/radiation therapy or major surgery within the last 4 weeks before start&#xD;
             of treatment&#xD;
&#xD;
          -  BMI &gt; 35&#xD;
&#xD;
          -  Pregnant or breast-feeding patients&#xD;
&#xD;
          -  Alcohol or drug abuse&#xD;
&#xD;
          -  Use of drugs that can influence hepatic function (e.g. phenytoin or phenobarbital)&#xD;
&#xD;
          -  Use of anticoagulants&#xD;
&#xD;
          -  Any reason why, in the opinion of the investigator, the patient should not participate&#xD;
             in the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kjersti Flatmark, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Svein Dueland, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oslo University Hospital- The Norwegian Radium Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>August 8, 2014</study_first_submitted>
  <study_first_submitted_qc>August 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2014</study_first_posted>
  <last_update_submitted>May 24, 2017</last_update_submitted>
  <last_update_submitted_qc>May 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Svein Dueland</investigator_full_name>
    <investigator_title>Senior consultant medical oncology</investigator_title>
  </responsible_party>
  <keyword>Peritoneal Carcinomatosis</keyword>
  <keyword>Peritoneal Metastasis</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Cytoreductive surgery</keyword>
  <keyword>HIPEC</keyword>
  <keyword>Intraperitoneal treatment</keyword>
  <keyword>Immunotoxin</keyword>
  <keyword>MOC31PE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunotoxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

